Vincent N Thijs1, Johannes Brachmann2, Carlos A Morillo2, Rod S Passman2, Tommaso Sanna2, Richard A Bernstein2, Hans-Christoph Diener2, Vincenzo Di Lazzaro2, Marilyn M Rymer2, Laurence Hogge2, Tyson B Rogers2, Paul D Ziegler2, Manish D Assar2. 1. From the Florey Institute of Neuroscience and Mental Health and Austin Health Department of Neurology (V.N.T.), Heidelberg, Australia; Hospital Klinikum Coburg (J.B.), Teaching Hospital of the University of Würzburg, Coburg, Germany; Population Health Research Institute (C.A.M.), McMaster University, Hamilton, Canada; Northwestern University Feinberg School of Medicine (R.S.P.), Chicago, IL; Institute of Cardiology (T.S.), Catholic University of the Sacred Heart, Rome, Italy; Davee Department of Neurology (R.A.B.), Northwestern University, Chicago, IL; Department of Neurology (H.-C.D.), University Hospital Essen University Duisburg-Essen, Germany; Institute of Neurology (V.D.L.), University Campus Bio-Medico of Rome, Rome, Italy; University of Kansas Medical Center (M.M.R.), Kansas City; Medtronic (L.H.), Maastricht, Netherlands; Medtronic (T.B.R., P.D.Z.), Mounds View, Minneapolis, MN; and Baylor University Medical Center (M.D.A.), Dallas, TX. vincent.thijs@florey.edu.au. 2. From the Florey Institute of Neuroscience and Mental Health and Austin Health Department of Neurology (V.N.T.), Heidelberg, Australia; Hospital Klinikum Coburg (J.B.), Teaching Hospital of the University of Würzburg, Coburg, Germany; Population Health Research Institute (C.A.M.), McMaster University, Hamilton, Canada; Northwestern University Feinberg School of Medicine (R.S.P.), Chicago, IL; Institute of Cardiology (T.S.), Catholic University of the Sacred Heart, Rome, Italy; Davee Department of Neurology (R.A.B.), Northwestern University, Chicago, IL; Department of Neurology (H.-C.D.), University Hospital Essen University Duisburg-Essen, Germany; Institute of Neurology (V.D.L.), University Campus Bio-Medico of Rome, Rome, Italy; University of Kansas Medical Center (M.M.R.), Kansas City; Medtronic (L.H.), Maastricht, Netherlands; Medtronic (T.B.R., P.D.Z.), Mounds View, Minneapolis, MN; and Baylor University Medical Center (M.D.A.), Dallas, TX.
Abstract
OBJECTIVE: We assessed predictors of atrial fibrillation (AF) in cryptogenic stroke (CS) or transient ischemic attack (TIA) patients who received an insertable cardiac monitor (ICM). METHODS: We studied patients with CS/TIA who were randomized to ICM within the CRYSTAL AF study. We assessed whether age, sex, race, body mass index, type and severity of index ischemic event, CHADS2 score, PR interval, and presence of diabetes, hypertension, congestive heart failure, or patent foramen ovale and premature atrial contractions predicted AF development within the initial 12 and 36 months of follow-up using Cox proportional hazards models. RESULTS: Among 221 patients randomized to ICM (age 61.6 ± 11.4 years, 64% male), AF episodes were detected in 29 patients within 12 months and 42 patients at 36 months. Significant univariate predictors of AF at 12 months included age (hazard ratio [HR] per decade 2.0 [95% confidence interval 1.4-2.8], p = 0.002), CHADS2 score (HR 1.9 per one point [1.3-2.8], p = 0.008), PR interval (HR 1.3 per 10 milliseconds [1.2-1.4], p < 0.0001), premature atrial contractions (HR 3.9 for >123 vs 0 [1.3-12.0], p = 0.009 across quartiles), and diabetes (HR 2.3 [1.0-5.2], p < 0.05). In multivariate analysis, age (HR per decade 1.9 [1.3-2.8], p = 0.0009) and PR interval (HR 1.3 [1.2-1.4], p < 0.0001) remained significant and together yielded an area under the receiver operating characteristic curve of 0.78 (0.70-0.85). The same predictors were found at 36 months. CONCLUSION: Increasing age and a prolonged PR interval at enrollment were independently associated with an increased AF incidence in CS patients. However, they offered only moderate predictive ability in determining which CS patients had AF detected by the ICM.
OBJECTIVE: We assessed predictors of atrial fibrillation (AF) in cryptogenic stroke (CS) or transient ischemic attack (TIA) patients who received an insertable cardiac monitor (ICM). METHODS: We studied patients with CS/TIA who were randomized to ICM within the CRYSTAL AF study. We assessed whether age, sex, race, body mass index, type and severity of index ischemic event, CHADS2 score, PR interval, and presence of diabetes, hypertension, congestive heart failure, or patent foramen ovale and premature atrial contractions predicted AF development within the initial 12 and 36 months of follow-up using Cox proportional hazards models. RESULTS: Among 221 patients randomized to ICM (age 61.6 ± 11.4 years, 64% male), AF episodes were detected in 29 patients within 12 months and 42 patients at 36 months. Significant univariate predictors of AF at 12 months included age (hazard ratio [HR] per decade 2.0 [95% confidence interval 1.4-2.8], p = 0.002), CHADS2 score (HR 1.9 per one point [1.3-2.8], p = 0.008), PR interval (HR 1.3 per 10 milliseconds [1.2-1.4], p < 0.0001), premature atrial contractions (HR 3.9 for >123 vs 0 [1.3-12.0], p = 0.009 across quartiles), and diabetes (HR 2.3 [1.0-5.2], p < 0.05). In multivariate analysis, age (HR per decade 1.9 [1.3-2.8], p = 0.0009) and PR interval (HR 1.3 [1.2-1.4], p < 0.0001) remained significant and together yielded an area under the receiver operating characteristic curve of 0.78 (0.70-0.85). The same predictors were found at 36 months. CONCLUSION: Increasing age and a prolonged PR interval at enrollment were independently associated with an increased AF incidence in CS patients. However, they offered only moderate predictive ability in determining which CS patients had AF detected by the ICM.
Authors: Richard A Bernstein; Vincenzo Di Lazzaro; Marilyn M Rymer; Rod S Passman; Johannes Brachmann; Carlos A Morillo; Tommaso Sanna; Vincent Thijs; Tyson Rogers; Shufeng Liu; Paul D Ziegler; Hans-Christoph Diener Journal: Cerebrovasc Dis Date: 2015-07-11 Impact factor: 2.762
Authors: Christopher G Favilla; Erin Ingala; Jenny Jara; Emily Fessler; Brett Cucchiara; Steven R Messé; Michael T Mullen; Allyson Prasad; James Siegler; Mathew D Hutchinson; Scott E Kasner Journal: Stroke Date: 2015-04-07 Impact factor: 7.914
Authors: David J Gladstone; Paul Dorian; Melanie Spring; Val Panzov; Muhammad Mamdani; Jeff S Healey; Kevin E Thorpe Journal: Stroke Date: 2015-02-19 Impact factor: 7.914
Authors: Marco V Perez; Frederick E Dewey; Rachel Marcus; Euan A Ashley; Amin A Al-Ahmad; Paul J Wang; Victor F Froelicher Journal: Am Heart J Date: 2009-10 Impact factor: 4.749
Authors: David J Gladstone; Melanie Spring; Paul Dorian; Val Panzov; Kevin E Thorpe; Judith Hall; Haris Vaid; Martin O'Donnell; Andreas Laupacis; Robert Côté; Mukul Sharma; John A Blakely; Ashfaq Shuaib; Vladimir Hachinski; Shelagh B Coutts; Demetrios J Sahlas; Phil Teal; Samuel Yip; J David Spence; Brian Buck; Steve Verreault; Leanne K Casaubon; Andrew Penn; Daniel Selchen; Albert Jin; David Howse; Manu Mehdiratta; Karl Boyle; Richard Aviv; Moira K Kapral; Muhammad Mamdani Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: Caroline S Fox; Helen Parise; Ralph B D'Agostino; Donald M Lloyd-Jones; Ramachandran S Vasan; Thomas J Wang; Daniel Levy; Philip A Wolf; Emelia J Benjamin Journal: JAMA Date: 2004-06-16 Impact factor: 56.272
Authors: Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger Journal: PLoS Med Date: 2007-10-16 Impact factor: 11.069
Authors: Karl Georg Haeusler; Klaus Gröschel; Martin Köhrmann; Stefan D Anker; Johannes Brachmann; Michael Böhm; Hans-Christoph Diener; Wolfram Doehner; Matthias Endres; Christian Gerloff; Hagen B Huttner; Manfred Kaps; Paulus Kirchhof; Darius Günther Nabavi; Christian H Nolte; Waltraud Pfeilschifter; Burkert Pieske; Sven Poli; Wolf Rüdiger Schäbitz; Götz Thomalla; Roland Veltkamp; Thorsten Steiner; Ulrich Laufs; Joachim Röther; Rolf Wachter; Renate Schnabel Journal: Clin Res Cardiol Date: 2018-04-27 Impact factor: 5.460